A second-generation inhaled insulin for diabetes mellitus

American Journal of Health-System Pharmacy

Volumn 72, Issue 14, 2015, Pages 1181-1187

  Ledet, Grace ^a   Graves, Richard A ^a   Bostanian, Levon A ^b   Mandal, Tarun K ^c  

^a Department of Research ^*  (United States)

^b Department of Senior Research ^*  (United States)

^c XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXCIPIENT; FUMARYL DLKETOPIPERAZLNE; GLYCOSYLATED HEMOGLOBIN; HUMAN INSULIN; INSULIN ANTIBODY; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO; LONG ACTING INSULIN; PLACEBO; RECOMBINANT HUMAN INSULIN; SHORT ACTING INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN;

ADULT; AGED; BLOOD GLUCOSE MONITORING; COUGHING; DIABETIC KETOACIDOSIS; DISEASE DURATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRY POWDER INHALER; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG CANCER; LUNG FLUID; LUNG FUNCTION TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT CONTRAINDICATION; TREATMENT DURATION; BLOOD; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; PROCEDURES;

ADMINISTRATION, INHALATION; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84957695496     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp140540     Document Type: Review

References (33)

1. Quianzon CC, Cheikh I. History of insulin. J Community Hosp Intern Med Perspect. 2012; 2(2): 18701.
2. Banting FG, Best CH, Collip JB et al. Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. 1922.CMA J. 1991; 145:1281-6.
3. Heinemann L. Variability of insulin absorption and insulin action. Diabetes - Teclmol Ther. 2002; 4:673-82.
4. Lee VH. Changing needs in drug delivery in the era of peptide and protein drugs. In: Lee VH, cd. Peptide and protein drug delivery. New York: Marcel Dekker; 1991:1-56.
5. Mandal TK. Inhaled insulin for diabetes mellitus. Am J Health-Syst Pharm. 2005; 62:1359-64.
6. Mack GS. Pfizer dumps Exubera. Mat Biotechnol. 2007; 25:1331-2.
7. Pfizer Inc. Pfizer statement on Exubera labeling update in the United States (April 8, 2008). www.pfizer.com/news/press-release/press-release-archive-detail/pfizer-statemcnt-on-exubera-labeling-update-in-the-united-states (accessed 2014 Sep 30).
8. Leone-Bay A, Grant M. Technosphere/insulin: mimicking endogenous insulin release. In: Rathbone M, Hadgraft J, Roberts M, Lane M, eds. Modified-release drug delivery technology. 2nd ed., vol. 2. New York: Informa Healthcare USA; 2008:673-9.
9. Richardson PC, Boss AH. Technosphere insulin technology. Diabetes Techndl Ther. 2007; 9(suppl l):S65-S72.
10. Bindra S, Cefalu WT. Exubera. Inhale therapeutic systems. Curr Opin Investig Drugs. 2002; 3:758-62.
11. MannKind Corporation. MannKind reports positive data from a phase 3 clinical study of Afrezza in patients with type 2 diabetes, www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-newsArticle-print&ID=1847440&highlight= (accessed 2014 Sep 30).
12. Potocka E, Cassidy JP, Haworth P et al. Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. J Diabetes Sci Technol. 2010;4:1164-73.
13. Cassidy JP, Amin N, Marino M et al. Insulin lung deposition and clearance following Technosphere insulin inhalation powder administration. Pharm Res. 2011; 28:2157-64.
14. Rosenstock J, Lorber DL, Gnudi L et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: A multicentre randomized trial. Lancet. 2010; 375:2244- 53.
15. MannKind Corporation. Briefing document: Endocrinologic and Metabolic Drugs Advisory Committee, April 01, 2014. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM390865.pdf (accessed 2014 Oct 28).
16. MannKind Corporation. Device technology patient-focused dry powder inhalers. www.mannkindcorp.com/our-technology-inhalers.htm (accessed 2014 Oct 1).
17. NovoLog (insulin aspart [rDNA origin 1 injection) package insert. Princeton, NJ: Novo Nordisk Inc.; 2013.
18. McAuley D. Rapid-acting analogueswww.globalrph.com/rapid-acting-analogues.htm (accessed 2014 Nov 6).
19. Humalog (insulin lispro injection, USP [rDNA origin]) package insert. Indianapolis, IN: Lilly USA, LLC; 2013.
20. Apidra (insulin glulisine [rDNA origin] injection) package insert. Bridgewater, NJ: sanofi-aventis U.S.; 2009.
21. Humulin R (insulin human injection, USP [rDNA origin]) package insert. Indianapolis, IN: Lilly USA, LLC; 2011.
22. Novolin R (regular, human insulin [rDNA origin] USP) package insert. Princeton, NJ: Novo Nordisk Inc.; 2012.
23. Pfützner A, Mann AE, Steiner SS. Technosphere/Insulin - A new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther. 2002; 4:589-94.
24. Rave K, Heise T, Pfutzner A et al. Coverage of postprandial blood glucose excursions with inhaled Technosphere Insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care. 2007; 30:2307-8.
25. Rosenstock J, Bergenstal R, DeFronzo RA et al. Efficacy and safety of Technosphere inhaled insulin compared with Techno sphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care. 2008; 31:2177-82.
26. Kamimura M, Izumi S, Hamamoto Y et al. Superiority of nebulized corticosteroids over dry powder inhalers in certain patients with cough variant asthma or cough-predominant asthma. Allergol Int. 2012;61:411-7.
27. Neumiller JJ, Mai YL, Setter SM et al. Inhaled, dry powder insulin. U.S. Pharm. 2007; 32(10):3-8.
28. Aldasouqi S, Sheikh A, Klosterman P et al. Hypoglycemia in patients with diabetes on antidiabetic medications who fast for laboratory tests. Diabetes Care. 2011; 34:e52.
29. Garg SK, McGill IB, Rosenstock J et al. Technosphere Insulin vs insulin lispro in patients with type 1 diabetes using multiple daily injections. Presentation at 71st Annual Scientific Sessions of the American Diabetes Association. San Diego, CA; 2011 Jun 24-28.
30. Skyler JS, Weinstock RS, Raskin P et al., for the Inhaled Insulin Phase III Type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: A 6-month, randomized, comparative trial. Diabetes Care. 2005; 28:1630-5.
31. Raskin P, Heller S, Honka M et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere insulin or usual antidiabe- Tes treatment: A randomized trial. Diabetes Obes Metab. 2012; 14:163-73.
32. National Cancer Institute. Surveillance Epidemiology and End Results: SEER stat fact sheets: lung and bronchus, http://seer.cancer.gov/statfacts/html/lungb.html (accessed 2014 Oct 28).
33. Afrezza (insulin human) package insert. Danbury, CT: MannKind Corporation; 2014.